Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CDH3/MSLN BiTE antibody AMG 305

A dual-targeting bispecific antibody and T-cell engager (BiTE) co-targeting both the human tumor-associated antigens (TAAs) cadherin-3 (CDH3; placental cadherin; P-cadherin) and mesothelin (MSLN) on tumor cells and CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CDH3/MSLN BiTE antibody AMG 305 binds with specificity to tumor cells co-expressing CDH3 and MSLN antigens and CD3 on cytotoxic T-lymphocytes (CTLs). This results in the cross-linking of T cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against CDH3- and MSLN-co-expressing tumor cells. CDH3 is a member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. Binding of both CDH3 and MSLN allows for increased specificity in targeting these TAAs that may be expressed at low levels on the tumor surface while limiting activity against normal cells that express only one of the target antigens.
Synonym:CDH3/MSLN bispecific T-cell engager AMG 305
CDH3xMSLN bispecific T-cell engager AMG 305
Code name:AMG 305
AMG-305
AMG305
Search NCI's Drug Dictionary